Tatva Chintan Pharma Chem Ltd
BSE:543321

Watchlist Manager
Tatva Chintan Pharma Chem Ltd Logo
Tatva Chintan Pharma Chem Ltd
BSE:543321
Watchlist
Price: 1 636.75 INR 2.39%
Market Cap: ₹38.3B

Wall St Price Targets

TATVA Price Targets Summary
Tatva Chintan Pharma Chem Ltd

Wall Street analysts forecast TATVA stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TATVA is 1 467.71 INR with a low forecast of 841.27 INR and a high forecast of 2 047.68 INR.

Lowest Forecast
Price Target
841.27 INR
49% Downside
Average Forecast
Price Target
1 467.71 INR
10% Downside
Highest Forecast
Price Target
2 047.68 INR
25% Upside
Tatva Chintan Pharma Chem Ltd Competitors:
Price Targets
CMI
Cummins Inc
36% Upside

Revenue
Forecast

12% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
12% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 26%.

Gross Profit
Forecast

15% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
15% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 2 years is 26%.

Operating Income
Forecast

1% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss
1% / Year
Past Growth
52% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Over the last 6 years, the compound annual growth rate for Operating Income has been 1%. The projected CAGR for the next 2 years is 52%.

Pre-Tax Income
Forecast

3% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss
3% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 2 years is 44%.

Net Income
Forecast

2% / Year
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
2% / Year
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 6 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 2 years is 46%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is TATVA's stock price target?
Price Target
1 467.71 INR

According to Wall Street analysts, the average 1-year price target for TATVA is 1 467.71 INR with a low forecast of 841.27 INR and a high forecast of 2 047.68 INR.

What is the Revenue forecast for Tatva Chintan Pharma Chem Ltd?
Projected CAGR
26%

Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 26%.

What is the Gross Profit forecast for Tatva Chintan Pharma Chem Ltd?
Projected CAGR
26%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 2 years is 26%.

What is the Operating Income forecast for Tatva Chintan Pharma Chem Ltd?
Projected CAGR
52%

Over the last 6 years, the compound annual growth rate for Operating Income has been 1%. The projected CAGR for the next 2 years is 52%.

What is the Pre-Tax Income forecast for Tatva Chintan Pharma Chem Ltd?
Projected CAGR
44%

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 2 years is 44%.

What is the Net Income forecast for Tatva Chintan Pharma Chem Ltd?
Projected CAGR
46%

Over the last 6 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 2 years is 46%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett